NEW YORK – CareDx and Veracyte said on Thursday that they have signed an agreement to make CareDx the exclusive worldwide commercialization partner for solid organ transplant rejection tests on Veracyte's nCounter Flex Analysis diagnostic platform.
NEW YORK – CareDx and Veracyte said on Thursday that they have signed an agreement to make CareDx the exclusive worldwide commercialization partner for solid organ transplant rejection tests on Veracyte's nCounter Flex Analysis diagnostic platform.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.